Skip to content

Effects of penehyclidine hydrochloride combined with dexmedetomidine on postoperative cognitive function and pulmonary function in patients undergoing cardiopulmonary bypass: a randomized controlled trial.

Effects of penehyclidine hydrochloride combined with dexmedetomidine on postoperative cognitive function and pulmonary function in patients undergoing cardiopulmonary bypass

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039610
Enrollment
Unknown
Registered
2020-11-03
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative cognitive dysfunction, postoperative pulmonary complications

Interventions

Group P:Penehyclidine hydrochloride 0.04mg /kg, Half of penehyclidine was injected intravenously 10 minutes before anesthesia, and the other half was injected immediately after cardiopulmonary bypass
Group D:Dexmedetomidine is continuously pumped for 0.5 ug/kg/h
Group PD:Half of penehyclidine was injected intravenously 10 minutes before anesthesia, and the other half was injected immediately after cardiopulmonary bypass
Dexmedetomidine is continuously pumped for 0.5 ug/kg/h.

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Subjects aged 20-65 years; 2. Subjects weighing 40-66 kg (BMI 18.5-23.9); 3. ASA II ~ II I objects; 4. Subjects of cardiac function classification I ~ II.

Exclusion criteria

Exclusion criteria: 1. Patients with mini mental state examination (MMSE) <= 23 points, 2. Glaucoma patients; 3. Patients with prostatic hypertrophy; 4. Patients with severe vision or hearing impairment; 5. Illiteracy and / or communication difficulties related to pronunciation or dialect, 6. Patients with acute or chronic infectious diseases, 7. Patients taking anti-inflammatory drugs, immunosuppressants or psychotropic drugs 8. Patients with lung, brain, liver, kidney and other organ diseases, 9. Patients with endocrine system diseases, 10. Patients with stroke or other neuropsychiatric diseases in the first 6 months, 11. Patients with history of hyperlipidemia, carotid atherosclerosis or stenosis, 12. Patients with poor preoperative pulmonary oxygenation, finger pulse oxygen < 90%, pure oxygen inhalation, finger pulse oxygen < 95%; 13. Patients who refuse or are discharged accidentally.

Design outcomes

Primary

MeasureTime frame
P (A-a) DO2;Oxygenation index (OI);respiratory index (RI);Respiratory parameters (tidal volume, respiratory rate, airway peak pressure, mean airway pressure);Extubation time;ICU staying;Secondary intubation rate;Postoperative pulmonary complications;Cognitive status;Delirium assessment;arterial blood gas analysis;Blood gas analysis of the bulb of right internal jugular vein;lactic acid;blood sugar;Arterial jugular bulb oxygen content difference;cerebral extraction of oxygen;Regional cerebral oxygen saturation;S100ß;Neuron specific enolase (NSE);Glial fibrillary acidic protein (GFAP);surfactant-associated protein-A (SP-A);Tumor necrosis factor - a (TNF -a);Interleukin-6 (IL-6);C-reactive protein (CRP);heart rate;Invasive blood pressure;mean arterial pressure;Central venous pressure;Pulse oxygen saturation (SPO2);Urine output;

Secondary

MeasureTime frame
Cardiopulmonary bypass time;Operation time;Aortic clamping time;Vena cava occlusion time;Minimum body temperature;Postoperative complications;The length of hospital stay;Numerical Rating Scale (NRS);

Countries

China

Contacts

Public ContactYizhi Lu

The First Affiliated Hospital of Guangxi Medical University

175171136@qq.com+86 13457057161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026